<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931460</url>
  </required_header>
  <id_info>
    <org_study_id>1045</org_study_id>
    <nct_id>NCT03931460</nct_id>
  </id_info>
  <brief_title>Feasibility of Medical Abortion by Telemedicine in Mexico</brief_title>
  <official_title>Feasibility of Medical Abortion by Telemedicine in Mexico</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to obtain preliminary data on the safety, acceptability, and
      feasibility of direct-to-consumer telemedicine abortion in Mexico.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pregnancy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical Abortion</intervention_name>
    <description>Medical Abortion</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women seeking abortion
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman is pregnant and desires a medical abortion by remote consult (TeleILE)

          -  Woman has access to internet or equipment for a remote consult

          -  Woman can provide address to which abortifacient medications will be mailed

          -  Woman reports no contraindications to medical abortion

          -  The study site does not suspect an ectopic pregnancy or nonviable pregnancy

          -  The gestational age allows sufficient time for the woman to take the mifepristone on
             or before 70 days of gestation

          -  A feasible plan is made that the woman agrees to confirm complete abortion and to seek
             care to manage incomplete abortion complications

          -  The woman understands and is likely to comply with study instructions and has granted
             informed consent to participate in the study.

        Exclusion Criteria:

          -  Medically ineligible for procedure.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melanie Pena, MPH, MA</last_name>
    <phone>(212) 448-1230</phone>
    <email>mpena@gynuity.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuel Bousiéguez, MBA</last_name>
    <phone>(212) 448-1230</phone>
    <email>mbousieguez@gynuity.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica AMASS</name>
      <address>
        <city>San Cristobal de las Casas</city>
        <state>Chiapas</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karla Mercado Gonzalez, MD</last_name>
      <phone>55-4576-4241</phone>
    </contact>
    <investigator>
      <last_name>Laura Miranda Arteaga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servicios Humanitarios en Salud Sexual y Reproductiva (SHSSR)</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Peniche Quintal, MD</last_name>
      <phone>999-127-8275</phone>
    </contact>
    <investigator>
      <last_name>Sandra Peniche Quintal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atención Integral en Ginecología,Medieg A.C.</name>
      <address>
        <city>Mexico City</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irving Geovanni Ortiz Salgado</last_name>
      <phone>55 5068-1903</phone>
    </contact>
    <investigator>
      <last_name>César Ruiz Cruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Atención Integral a la Pareja, A.C. (CIPA)</name>
      <address>
        <city>Mexico City</city>
        <zip>04460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cruz Guerrero</last_name>
      <phone>55 4937 3252</phone>
    </contact>
    <investigator>
      <last_name>Ana María Camarillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gineclinic</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saraheli Lara, RN</last_name>
      <phone>55-4554-6209</phone>
    </contact>
    <investigator>
      <last_name>Karla Figueroa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

